Active Ingredient History
Abiraterone acetate (trade name Zytiga) is a prodrug to the abiraterone, steroidal compound with antiandrogen activity and a 17 α-hydroxylase/C17,20-lyase (CYP17) inhibitor. It is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone acetate is converted in vivo to abiraterone which inhibits CYP17, enzyme expressed in testicular, adrenal, and prostatic tumor tissues and required for androgen biosynthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels. Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Prostatic Neoplasms, Castration-Resistant (approved 2011)
Abiraterone Acetate (Phase 3)
Adrenal Hyperplasia, Congenital (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Androgens (Phase 3)
Anemia (Phase 1)
Antineoplastic Agents (Phase 3)
Antineoplastic Agents, Hormonal (Phase 3)
Astrocytoma (Phase 1)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Transitional Cell (Phase 2)
Castration (Phase 3)
Colorectal Neoplasms (Phase 1)
Congenital Hyperinsulinism (Phase 2)
COVID-19 (Phase 3)
Cushing Syndrome (Phase 2)
Cyclin-Dependent Kinase 4 (Phase 3)
Cyclin-Dependent Kinase 6 (Phase 3)
Cytochrome P-450 Enzyme System (Phase 3)
DNA Repair-Deficiency Disorders (Phase 2)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Drug Therapy, Combination (Phase 2)
Enzyme Inhibitors (Phase 3)
Glioblastoma (Phase 1)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 1)
Hormones (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Diseases (Phase 1)
Lymphoma (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Metabolic Diseases (Phase 1)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Pancreatic Neoplasms (Phase 1)
Papillomavirus Infections (Phase 3)
Pharmaceutical Preparations (Phase 2)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 1)
Physiological Effects of Drugs (Phase 3)
Plasma (Early Phase 1)
Polymorphism, Genetic (Early Phase 1)
Postmenopause (Phase 2)
Prednisolone (Phase 3)
Prednisone (Phase 3)
Primary Myelofibrosis (Phase 1)
Prostatectomy (Phase 2)
Renal Insufficiency (Phase 1)
Salivary Gland Neoplasms (Phase 2)
Steroid Synthesis Inhibitors (Phase 3)
Triple Negative Breast Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 2)
Urogenital Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
